We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elite Pharmaceuticals Stock Gains Post Q2 Earnings, Revenues Up Y/Y
Read MoreHide Full Article
Shares of Elite Pharmaceuticals, Inc. (ELTP - Free Report) have gained 49.4% since the company reported its earnings for the quarter ended Sept. 30, 2026, outperforming the S&P 500 Index, which declined 3.8% over the same period. Over the past month, the stock has surged 46.2%, against the S&P 500's 5.6% decline.
Elite Pharmaceuticals’ Earnings Snapshot
Elite Pharmaceuticals reported second-quarter fiscal 2027 revenues of $40.1 million, up 10.4% from $36.3 million in the year-ago quarter. The increase primarily reflected stronger sales of amphetamine and naltrexone products under the Elite label. Net income increased 26.4% to $17.3 million from $13.7 million, while basic earnings per share improved to $0.02 from $0.01. Diluted earnings remained unchanged at $0.01 per share.
ELTP operates through a single reportable segment comprising Abbreviated New Drug Application products. Segment operating income increased 11.2% to $14.1 million from $12.7 million.
ELTP's Other Key Metrics
Gross profit increased 13.6% to $15.9 million from $14.1 million, with gross margin improving to 40% from 39%. Operating income rose 20.8% to $9.9 million from $8.2 million.
Research and development expenses increased 35.5% to $1.9 million from $1.4 million, reflecting higher product development investments. General and administrative expenses declined 6.1% to $3.8 million from $4 million.
Direct wholesaler revenues increased 56.6% to $18.2 million from $11.7 million, while indirect wholesaler revenues declined 11% to $21.8 million from $24.5 million. Revenues from unscheduled products increased to $5.9 million from $2.6 million.
Cash and cash equivalents were $34.9 million as of Sept. 30, 2026, compared with $29.8 million as of March 31, 2026. Total liabilities declined to $22.1 million from $39.4 million. Operating cash flow for the six months ended Sept. 30, 2026, decreased to $6.9 million from $19.9 million a year earlier.
CFO Carter Ward attributed the decline in operating cash flow partly to changes in working capital. During the September quarter, accounts receivable and inventory increased by $4.8 million, reflecting higher sales activity and inventory requirements. Management emphasized that the timing of inventory purchases, sales and customer collections influenced cash generation.
Elite Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Management attributed revenue growth to expanding mixed amphetamine salts and opioid addiction treatment product lines, alongside higher lisdexamfetamine volumes and stabilizing pricing.
CFO Carter Ward emphasized that revenues have become more diversified, reducing dependence on lisdexamfetamine. Meanwhile, CEO Nasrat Hakim highlighted the established ADHD portfolio as an important growth foundation.
Management also noted contributions from recently introduced products, including ropinirole, while acknowledging that certain newly launched pain management products remain in their early commercialization stages.
Factors Affecting ELTP's Results
Generic competition and earlier pricing declines in lisdexamfetamine continued to influence Elite Pharmaceuticals' revenue mix. However, stabilizing market conditions and stronger sales across other products supported quarterly growth.
The quarter's net income also benefited from a $9.7 million noncash gain related to changes in the fair value of derivative warrant liabilities. Consequently, reported profitability reflected both operating improvements and nonoperating valuation effects.
Management identified regulatory quotas affecting lisdexamfetamine and potential manufacturing capacity limitations as constraints on further expansion.
Elite Pharmaceuticals’ Growth Outlook
Elite Pharmaceuticals expects its anticoagulant development program to progress toward regulatory milestones in 2027, with a potential commercial launch in 2028. Management also anticipates advancing anticonvulsant and diabetes product development through additional bioequivalence studies.
ELTP plans to expand its manufacturing footprint from approximately 85,000 square feet to 130,000 square feet in 2027.
Management is also targeting a Nasdaq uplisting by March 2027, subject to shareholder approvals, regulatory requirements and exchange acceptance.
ELTP's Other Developments
During the earnings call, management disclosed that Elite Pharmaceuticals had received a verbal acquisition proposal through its investment bankers. Following a board review, the company decided against pursuing the proposal and temporarily suspended merger and acquisition negotiations.
Management intends to revisit strategic discussions in 2027 after further progress in product development and manufacturing expansion. For now, ELTP is prioritizing organic growth, pipeline diversification and operational capacity improvements.
Image: Bigstock
Elite Pharmaceuticals Stock Gains Post Q2 Earnings, Revenues Up Y/Y
Shares of Elite Pharmaceuticals, Inc. (ELTP - Free Report) have gained 49.4% since the company reported its earnings for the quarter ended Sept. 30, 2026, outperforming the S&P 500 Index, which declined 3.8% over the same period. Over the past month, the stock has surged 46.2%, against the S&P 500's 5.6% decline.
Elite Pharmaceuticals’ Earnings Snapshot
Elite Pharmaceuticals reported second-quarter fiscal 2027 revenues of $40.1 million, up 10.4% from $36.3 million in the year-ago quarter. The increase primarily reflected stronger sales of amphetamine and naltrexone products under the Elite label. Net income increased 26.4% to $17.3 million from $13.7 million, while basic earnings per share improved to $0.02 from $0.01. Diluted earnings remained unchanged at $0.01 per share.
ELTP operates through a single reportable segment comprising Abbreviated New Drug Application products. Segment operating income increased 11.2% to $14.1 million from $12.7 million.
ELTP's Other Key Metrics
Gross profit increased 13.6% to $15.9 million from $14.1 million, with gross margin improving to 40% from 39%. Operating income rose 20.8% to $9.9 million from $8.2 million.
Research and development expenses increased 35.5% to $1.9 million from $1.4 million, reflecting higher product development investments. General and administrative expenses declined 6.1% to $3.8 million from $4 million.
Direct wholesaler revenues increased 56.6% to $18.2 million from $11.7 million, while indirect wholesaler revenues declined 11% to $21.8 million from $24.5 million. Revenues from unscheduled products increased to $5.9 million from $2.6 million.
Cash and cash equivalents were $34.9 million as of Sept. 30, 2026, compared with $29.8 million as of March 31, 2026. Total liabilities declined to $22.1 million from $39.4 million. Operating cash flow for the six months ended Sept. 30, 2026, decreased to $6.9 million from $19.9 million a year earlier.
CFO Carter Ward attributed the decline in operating cash flow partly to changes in working capital. During the September quarter, accounts receivable and inventory increased by $4.8 million, reflecting higher sales activity and inventory requirements. Management emphasized that the timing of inventory purchases, sales and customer collections influenced cash generation.
Elite Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Elite Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Elite Pharmaceuticals Inc. Quote
Elite Pharmaceuticals’ Growth Drivers
Management attributed revenue growth to expanding mixed amphetamine salts and opioid addiction treatment product lines, alongside higher lisdexamfetamine volumes and stabilizing pricing.
CFO Carter Ward emphasized that revenues have become more diversified, reducing dependence on lisdexamfetamine. Meanwhile, CEO Nasrat Hakim highlighted the established ADHD portfolio as an important growth foundation.
Management also noted contributions from recently introduced products, including ropinirole, while acknowledging that certain newly launched pain management products remain in their early commercialization stages.
Factors Affecting ELTP's Results
Generic competition and earlier pricing declines in lisdexamfetamine continued to influence Elite Pharmaceuticals' revenue mix. However, stabilizing market conditions and stronger sales across other products supported quarterly growth.
The quarter's net income also benefited from a $9.7 million noncash gain related to changes in the fair value of derivative warrant liabilities. Consequently, reported profitability reflected both operating improvements and nonoperating valuation effects.
Management identified regulatory quotas affecting lisdexamfetamine and potential manufacturing capacity limitations as constraints on further expansion.
Elite Pharmaceuticals’ Growth Outlook
Elite Pharmaceuticals expects its anticoagulant development program to progress toward regulatory milestones in 2027, with a potential commercial launch in 2028. Management also anticipates advancing anticonvulsant and diabetes product development through additional bioequivalence studies.
ELTP plans to expand its manufacturing footprint from approximately 85,000 square feet to 130,000 square feet in 2027.
Management is also targeting a Nasdaq uplisting by March 2027, subject to shareholder approvals, regulatory requirements and exchange acceptance.
ELTP's Other Developments
During the earnings call, management disclosed that Elite Pharmaceuticals had received a verbal acquisition proposal through its investment bankers. Following a board review, the company decided against pursuing the proposal and temporarily suspended merger and acquisition negotiations.
Management intends to revisit strategic discussions in 2027 after further progress in product development and manufacturing expansion. For now, ELTP is prioritizing organic growth, pipeline diversification and operational capacity improvements.